Author:
Ellingsen Espen Basmo,Mangsbo Sara M.,Hovig Eivind,Gaudernack Gustav
Abstract
Telomerase-based therapeutic cancer vaccines (TCVs) have been under clinical investigation for the past two decades. Despite past failures, TCVs have gained renewed enthusiasm for their potential to improve the efficacy of checkpoint inhibition. Telomerase stands as an attractive target for TCVs due to its almost universal presence in cancer and its essential function promoting tumor growth. Herein, we review tumor telomerase biology that may affect the efficacy of therapeutic vaccination and provide insights on optimal vaccine design and treatment combinations. Tumor types possessing mechanisms of increased telomerase expression combined with an immune permissive tumor microenvironment are expected to increase the therapeutic potential of telomerase-targeting cancer vaccines. Regardless, rational treatment combinations, such as checkpoint inhibitors, are likely necessary to bring out the true clinical potential of TCVs.
Subject
Immunology,Immunology and Allergy
Reference147 articles.
1. Gemcitabine and Capecitabine With or Without Telomerase Peptide Vaccine GV1001 in Patients With Locally Advanced or Metastatic Pancreatic Cancer (TeloVac): An Open-Label, Randomised, Phase 3 Trial;Middleton;Lancet Oncol,2014
2. Improved Survival With Ipilimumab in Patients With Metastatic Melanoma;Hodi;New Engl J Med,2010
3. Immuno-Oncology Drug Development Forges on Despite COVID-19;Upadhaya;Nat Rev Drug Discov,2020
4. Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma;Larkin;N Engl J Med,2019
5. Pembrolizumab Versus Ipilimumab in Advanced Melanoma (KEYNOTE-006): Post-Hoc 5-Year Results From an Open-Label, Multicentre, Randomised, Controlled, Phase 3 Study;Robert;Lancet Oncol,2019
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献